Prescription opioids continue to be the most frequently misused prescription drugs in the United States, having caused nearly 300,000 deaths over the past two decades. Signed into law in 2022, the No Pain Act expands Medicare reimbursement for specific non-opioid pain management options. Carolyn Liptak, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence, and Dr. Phil Mentler, Senior Consulting Director at Vizient join Program Host Stacy Lauderdale to discuss the implications of the No Pain Act, which took effect on January 1, 2025.

Guest speakers:

Carolyn Liptak, MBA, RPh

Pharmacy Executive Director

Vizient

Phillipe Mentler, Pharm.D, BCPS

Senior Consulting Director

Vizient

Host:

Stacy Lauderdale, Pharm.D, BCPS

Associate Vice President

Vizient

VerifiedRx Host

Show Notes:

[01:49-03:48] Background on the No Pain Act

[03:49-05:03] What is new as of January 1, 2025

[05:04-05:37] The difference between a hospital outpatient department versus an ambulatory surgical center

[05:38-06:30] Other drugs and or devices that are on the list other than Exparel

[06:31-07:42] What specifically prevents multi modal drugs and therapy from being added to the list

[07:43-08:24] Specific language that needs to be included in the FDA labeling for non-opioids to be considered for reimbursement under the Act

[08:25-10:50] Reimbursement basics of the NO PAIN Act

[14:32-15:44] Reimbursement

[15:45-17:04] The importance of opioids in pain management

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

Historically, Vizient has published the Pharmacy Market Outlook biannually. This year, we are introducing the Spend Management Outlook, which integrates the comprehensive insights from the Pharmacy Market Outlook with the Vizient Budget Impact Report. This new report enhances strategic planning by aligning pricing projections across the healthcare supply chain and providing key market insights. Dr. Carina Dolan, Associate Vice President of Clinical Oncology, Pharmacoeconomics, & Market Insights, and Jeff King, Director of Research and Intelligence at Vizient, join Program Host Carolyn Liptak to discuss the unique features and critical importance of the new Spend Management Outlook.

Guest speakers:

Carina Dolan, Pharm. D., MS Pharm, BCOP

Associate Vice President, Clinical Oncology, Pharmacoeconomics and Market Insights

Vizient

Jeff King

Research and Intelligence Director

Vizient

Host:

Carolyn Liptak, MBA, BS Pharm

VerifiedRx Host

Show Notes:

[01:06-01:56] Jeff’s background and role

[01:57-02:50] The transition from Pharmacy Market Outlook and Budget Impact Report to Spend Management Outlook

[02:51-03:28] Defining spend management

[03:29-04:43] Key insights into spend management categories med-surg and laboratory

[04:44-06:01] Key insights into spend management categories Capital equipment and physician preferences insights

[06:02-07:23] Enhancements to pharmacy projections of this edition

[07:24-08:39] Spend management projection methodology

[08:40-09:34] The spend management projections

Links | Resources:

Spend Management Outlook

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

We anticipate there will be some policy changes and important issues to watch with the inauguration of the 47th president of the United States. Vizient’s office of public policy and government relations monitors, educates and advocates on key items of interest. They share informative updates, comment on proposed rules from agencies like the Centers for Medicare and Medicaid Services and work with Congress on legislative priorities. Jenna Stern, Associate Vice President of Regulatory Affairs and Public Policy at Vizient joins Program Host Carolyn Liptak to discuss the change over.

Guest speakers:

Jenna Stern

Associate Vice President of Regulatory Affairs and Public Policy

Vizient

Host:

Carolyn Liptak, MBA, RPh

VerifiedRx Host

Show Notes:

[00:56-01:15] Jenna’s background

[01:16-02:38] Anticipation in DC since November

[02:39-04:26] What we should anticipate with the new Congress

[04:27-08:10] Trade and Tariffs

[08:11-10:37] What we should anticipate with the Executive Branch

[10:38-12:48] Policies to watch during transition

[12:48-13:34] Where listeners go for more information

[13:34-16:12] What issues are important to the new Congress

Links | Resources:

Vizient Public Policy and Government Relations

Vizient advocacy letters and Congressional statements

Legislative and regulatory summaries

China Tariffs document

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed